Market revenue in 2022 | USD 568.0 million |
Market revenue in 2030 | USD 1,007.8 million |
Growth rate | 7.4% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 54.67% in 2022. Horizon Databook has segmented the Canada hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
Canada is anticipated to witness lucrative growth in the coming years. Increasing disease awareness, improved screening, developments in its healthcare infrastructure, and growing healthcare expenditure per capita are among factors supporting market growth. According to an NCBI article, one in 10 people in Canada is affected with thyroid disease.
However, the diagnosis rate for thyroid is lower than expected in the country. According to Thyroid Foundation of Canada, the reason for low diagnosis rate is that people have accepted it as a common hereditary disorder, and the disease gets attention mostly when the gland gets awry. Such factors raise the demand for thyroid hormone replacement therapy. Increase in the prevalence of GHD is another factor expected to drive market growth.
In Canada, Turner syndrome is diagnosed in one out of every 2,500 live female births. According to Turner Syndrome Society of Canada, over 6,000 women are suffering from the disease in the country. Prader-Willi syndrome affects men and women equally; it occurs in one out of 15,000 births.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into Canada hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account